This is a routine governance filing with no immediate trading implications. Monitor upcoming pipeline catalysts for givastomig and VIS-101, and the next quarterly filing for any strategic or financial updates.
Price Chart
Executive Summary
NovaBridge Biosciences announced the appointment of Martin Dewhurst as an independent director and member of the Audit and Compensation Committees, replacing departing director Liu Xin. This is a routine governance change with no material financial impact — Dewhurst brings extensive life sciences consulting experience from McKinsey, but the filing contains no financial data, guidance, or operational updates. The appointment is neutral for the stock.
Key Facts
- Martin Dewhurst appointed as independent director effective September 8, 2026
- Dewhurst will serve on both the Audit Committee and Compensation Committee
- He previously co-led McKinsey's Global Life Sciences Practice for 7 years and co-founded the McKinsey Health Institute
- The appointment follows the departure of independent director Liu Xin
- No financial figures, guidance, or operational data were disclosed in the filing
Financial Impact
No financial impact — routine board appointment with no disclosed compensation or financial terms
Risk Factors
- No material risks disclosed in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-384355 |
| Document: nbp-ex99_1.htm | 0001193125-26-384355 |
| Document: 0001193125-26-384355-index-headers.html | 0001193125-26-384355 |
| Document: 0001193125-26-384355-index.html | 0001193125-26-384355 |
| Document: 0001193125-26-384355.txt | 0001193125-26-384355 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.49 | awaiting T+5 | — | $1.22 (−18.46%) |
Oct 25, 2026 1d ago | Press Release | $1.42 | awaiting T+5 | — | $1.22 (−14.44%) |
Oct 23, 2026 3d ago | 6-K | $1.37 | awaiting T+5 | — | $1.22 (−11.31%) |
Oct 13, 2026 13d ago | 6-K | $1.29 $1.43 | ▲ +10.47% | ▲ +11.62% | $1.22 (−5.81%) |
Sep 8, 2026 6w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.22 (−31.74%) |
Sep 8, 2026 6w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.22 (−31.74%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.22 (+36.39%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▼ −1.05% | ▼ −2.16% | $1.22 (−36.39%) |
Aug 20, 2026 9w ago | Press Release | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.22 (+36.39%) |
Jul 24, 2026 13w ago | 6-K | $1.78 $1.60 | ▼ −10.11% | ▼ −11.19% | $1.22 (−31.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers